美国临床肿瘤学会第49届年会

ASCO2013:标志物之VEGF及VEGFR的基因多态性与索拉非尼治疗毒性及疗效的相关

   2013-06-05
字体大小:

作者检测了73名肝癌患者的组织标本中的VEGF-A、VEGF-C及VEGFR-1,-2,-3分子的单核苷酸多态性(SNP)。发现VEGF-Ars833061T>C,rs699947C>A和rs2010963C>G多态性与各级不良反应及皮肤毒性反应显著相关。而具有各级不良反应和皮肤毒性反应的患者无进展生存期和总体生存期更佳(P值均小于0.05)。因此,对这些位点的基因检测可能有助于预测抗血管生成治疗的副作用及疗效。

摘要详情:

Abstract:

Background: The introduction of sorafenib for the treatment of advanced HCC radically changed patients’ clinical outcome. However response to treatment as well as toxicity are still largely unpredictable in the single patient. We previously reported that VEGF and VEGFR polymorphisms may have a predictive and prognostic role in this setting, but little is known about the possible correlation with toxicity. The aim of our study was to evaluate whether VEGF and VEGFR genotyping was able to correlate with toxicity in HCC patients receiving sorafenib.

Methods: 73 histological samples of HCC patients receiving sorafenib were tested for VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs). Patients time to progression (TTP), overall survival (OS) and toxicities were analysed.

Results: VEGF-A rs833061 T>C, rs699947 C>A and rs2010963 C>G polymorphisms were statistically significant associated with any grade global (respectively: p=0.031; p=0.018; p=0.003) and cutaneous toxicities (respectively: p=0.043; p=0.019; p=0.025). Furthermore patients with any grade global and cutaneous toxicities showed a better progression free survival and overall survival (global toxicity PFS: 7.0 vs 5.0 months, p=0.016; OS: 26.8 vs 13.0 months, p=0.023) (cutaneous toxicity PFS: 7.6 vs 5.1 months, p=0.033; OS: 22.7 vs 13.3 months, p=0.014)

Conclusions: In our analysis patients with polymorphism T at rs833061, C at rs699947 and C at rs2010963 showed a higher rate of toxicities and, accordingly to our previous report, this correlates with a better PFS and OS. Analysis of VEGF and its receptor genes polymorphisms represents a clinical tool to identify patients with favourable response to sorafenib presumably related to a more efficient control of tumour growth. The occurrence of toxicity could be an interesting clinical surrogate during sorafenib treatment and may help clinicians in a more cautious and aware management of HCC patients.

编辑: 又又    来源:丁香园

网友评论